Literature DB >> 18563175

Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia.

B F Goemans, C M Zwaan, S J H Vijverberg, A H Loonen, U Creutzig, K Hählen, D Reinhardt, B E S Gibson, J Cloos, G J L Kaspers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18563175     DOI： 10.1038/leu.2008.147

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

Review 1.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 2.  Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.

Authors:  Jeffrey Baron; Eunice S Wang
Journal:  Expert Rev Clin Pharmacol       Date:  2018-06-11       Impact factor: 5.045

Review 3.  Gemtuzumab ozogamicin in acute myeloid leukemia.

Authors:  C D Godwin; R P Gale; R B Walter
Journal:  Leukemia       Date:  2017-06-13       Impact factor: 11.528

4.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404

Review 5.  Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.

Authors:  Andrew J Cowan; George S Laszlo; Elihu H Estey; Roland B Walter
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

6.  ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.

Authors:  Roya Rafiee; Lata Chauhan; Todd A Alonzo; Yi-Cheng Wang; Ahlam Elmasry; Michael R Loken; Jessica Pollard; Richard Aplenc; Susana Raimondi; Betsy A Hirsch; Irwin D Bernstein; Alan S Gamis; Soheil Meshinchi; Jatinder K Lamba
Journal:  Blood Cancer J       Date:  2019-05-21       Impact factor: 11.037

7.  AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

Authors:  David B Rosen; Kimberly H Harrington; James A Cordeiro; Ling Y Leung; Santosh Putta; Norman Lacayo; George S Laszlo; Chelsea J Gudgeon; Donna E Hogge; Rachael E Hawtin; Alessandra Cesano; Roland B Walter
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.